Brian Long

807 total citations
22 papers, 462 citations indexed

About

Brian Long is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Brian Long has authored 22 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 15 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Brian Long's work include Virus-based gene therapy research (17 papers), CAR-T cell therapy research (15 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Brian Long is often cited by papers focused on Virus-based gene therapy research (17 papers), CAR-T cell therapy research (15 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Brian Long collaborates with scholars based in United States, United Kingdom and France. Brian Long's co-authors include Christian Vettermann, Stephen J. Zoog, Becky Schweighardt, Laurie Tsuruda, Sylvia Fong, Charles O’Neill, Boris Gorovits, Mark Milton, Gregory M. Hayes and Jennifer Holcomb and has published in prestigious journals such as Blood, The Journal of Immunology and Journal of Animal Ecology.

In The Last Decade

Brian Long

21 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Long United States 13 306 223 193 65 64 22 462
Romain Hardet France 9 297 1.0× 267 1.2× 148 0.8× 57 0.9× 63 1.0× 14 452
Marcelo Simon Sola France 8 428 1.4× 406 1.8× 134 0.7× 38 0.6× 80 1.3× 11 621
Elisa Masat Italy 10 216 0.7× 233 1.0× 86 0.4× 92 1.4× 52 0.8× 12 465
Geoffrey D. Keeler United States 9 217 0.7× 208 0.9× 100 0.5× 55 0.8× 46 0.7× 14 387
Carolyn Spencer United States 5 210 0.7× 182 0.8× 80 0.4× 15 0.2× 67 1.0× 5 344
Richard Van Rheeden United States 9 120 0.4× 265 1.2× 45 0.2× 15 0.2× 17 0.3× 10 398
Esperanza López‐Franco Spain 5 177 0.6× 217 1.0× 56 0.3× 13 0.2× 19 0.3× 6 317
Carl K. Edwards United States 7 87 0.3× 117 0.5× 44 0.2× 126 1.9× 27 0.4× 7 325
Zhiheng Huang China 12 98 0.3× 205 0.9× 38 0.2× 136 2.1× 14 0.2× 25 471
Wangko Lundström Sweden 6 54 0.2× 88 0.4× 81 0.4× 208 3.2× 21 0.3× 8 397

Countries citing papers authored by Brian Long

Since Specialization
Citations

This map shows the geographic impact of Brian Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Long more than expected).

Fields of papers citing papers by Brian Long

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Long. The network helps show where Brian Long may publish in the future.

Co-authorship network of co-authors of Brian Long

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Long. A scholar is included among the top collaborators of Brian Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Long. Brian Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miesbach, Wolfgang, Paul Batty, Pratima Chowdary, et al.. (2024). Adeno-associated virus-based gene therapy for hemophilia–addressing the gaps. Research and Practice in Thrombosis and Haemostasis. 9(1). 102673–102673. 4 indexed citations
2.
Braun, Manuela, Claudia Lange, Philipp Schatz, et al.. (2024). Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements. Molecular Therapy — Methods & Clinical Development. 32(1). 101217–101217. 11 indexed citations
3.
Ragni, Margaret V., Ype P. de Jong, Radosław Kaczmarek, et al.. (2024). Optimizing liver health before and after gene therapy for hemophilia A. Blood Advances. 8(19). 5203–5212. 4 indexed citations
4.
5.
Gorovits, Boris, George Buchlis, Michele Fiscella, et al.. (2023). Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy. The AAPS Journal. 25(3). 47–47. 18 indexed citations
6.
Pierce, Glenn F., Sylvia Fong, Brian Long, & Radosław Kaczmarek. (2023). Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia. Journal of Thrombosis and Haemostasis. 22(5). 1263–1289. 16 indexed citations
7.
Long, Brian, et al.. (2022). Confirmatory detection of neutralizing antibodies to AAV gene therapy using a cell-based transduction inhibition assay. Molecular Therapy — Methods & Clinical Development. 24. 222–229. 6 indexed citations
8.
Yang, Fan, Kathryn Patton, Brian Long, et al.. (2021). Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates. Gene Therapy. 29(1-2). 41–54. 21 indexed citations
9.
Gorovits, Boris, George Buchlis, Travis Harrison, et al.. (2021). Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays. The AAPS Journal. 23(6). 108–108. 32 indexed citations
10.
Patton, Kathryn, Mike T. Harrison, Brian Long, et al.. (2021). Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method. Molecular Therapy — Methods & Clinical Development. 22. 183–195. 24 indexed citations
11.
Gorovits, Boris, Michele Fiscella, Eugen Koren, et al.. (2020). Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays. The AAPS Journal. 22(2). 24–24. 35 indexed citations
12.
Long, Brian, P. Véron, Klaudia Kuranda, et al.. (2020). Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A. Molecular Therapy. 29(2). 597–610. 54 indexed citations
13.
Long, Brian, Jennifer Holcomb, Gregory M. Hayes, et al.. (2019). The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy. Molecular Therapy — Methods & Clinical Development. 13. 440–452. 55 indexed citations
14.
15.
Long, Brian, Jennifer Holcomb, Charles O’Neill, et al.. (2017). Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A. Blood. 130. 3332–3332. 2 indexed citations
16.
17.
Yates, Bridget, Brian Long, Laurie Tsuruda, et al.. (2017). Strategy to detect pre-existing immunity to AAV gene therapy. Gene Therapy. 24(12). 768–778. 79 indexed citations
18.
Melton, Andrew C., Troy Tompkins, Brian Long, et al.. (2016). Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome. Journal of Immunological Methods. 440. 41–51. 14 indexed citations
19.
Long, Brian, Troy Tompkins, Celeste Decker, et al.. (2016). Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study. Clinical Therapeutics. 39(1). 118–129.e3. 26 indexed citations
20.
Wong, Carmen P., Brian Long, Li Li, et al.. (2007). Identical β Cell-Specific CD8+ T Cell Clonotypes Typically Reside in Both Peripheral Blood Lymphocyte and Pancreatic Islets. The Journal of Immunology. 178(3). 1388–1395. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Romain Hardet Breakdown of academic impact, for papers by Marcelo Simon Sola Breakdown of academic impact, for papers by Elisa Masat Breakdown of academic impact, for papers by Geoffrey D. Keeler Breakdown of academic impact, for papers by Carolyn Spencer Breakdown of academic impact, for papers by Richard Van Rheeden Breakdown of academic impact, for papers by Esperanza López‐Franco Breakdown of academic impact, for papers by Carl K. Edwards Breakdown of academic impact, for papers by Zhiheng Huang Breakdown of academic impact, for papers by Wangko Lundström
Rankless by CCL
2026